Teverelix DP not checked

Antev Ltd.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
3 in total · 2 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Teverelix DP 540 mg Day 1 and 360 mg every 6 weeks from week 4 to week 16.”In the company’s words, NCT07457164 on ClinicalTrials.gov
Tested for
Advanced Prostate Cancer, GnRH Antagonist, Acute Urinary Retention, Benign Prostate Hypertrophy(BPH), Endometriosis Pelvic, Endometriosis Ovaries, Premenopausal, Endometriosis (Diagnosis) and 2 more
Main trialPhase 2
“The purpose of this clinical trial is to test the effectiveness of a dosing regimen of Teverelix DP castration rate defined as the cumulative probability of testosterone suppression to \< 0.5 ng/mL with the lower bound of the 95% confidence interval (CI) being \> 90% to meet the evaluation criteria for efficacy. The main question it aims to answer is: •Is the dosing regimen of Teverelix DP in this study effective at achieving the required testosterone suppression to castrate levels. Participants will * Receive a single loading dose consisting of 3 injections of teverelix DP (180 mg IM +…”In the company’s words, NCT07457164 on ClinicalTrials.gov

Other drugs for Advanced Prostate Cancer

All 194 drugs for Advanced Prostate Cancer

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Sep 2027 A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer
Phase 2Not yet recruiting May 2028 Study of Teverelix DP on Prostate Volume, Urinary Function and Clinical Outcomes Following Acute Urinary Retention
Phase 2Not yet recruiting Dec 2029 PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Teverelix DP

Following is part of Solo: you see every change to Teverelix DP the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in